Merck Confirms Favorable Cardiovascular Safety Profile of Vioxx
May 22nd, 2001. In response to news and analyst reports of data the Company first released a year ago, Merck & Co., Inc. today reconfirmed the favorable cardiovascular safety profile of Vioxx(R) (rofecoxib), its medicine that selectively inhibits COX-2. Vioxx was approved by the Food and Drug Administration in May 1999 for the ... [More >>]

